In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Can-Fite Biopharma Ltd. Trade Record

AMEX:CANF Can-Fite Biopharma Ltd stock gains 12.89% Exit Jan 18, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CANF Jan 5, 2018, priceSeries
About Can-Fite Biopharma Ltd

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases, as well as sexual dysfunction. It offers CF101, which has completed Phase II/III clinical trials for the treatment of psoriasis; completed Phase II clinical trials for the treatment of rheumatoid arthritis; completed Phase I clinical study for the treatment of osteoarthritis; and completed Phase I study for the treatment of uveitis, as well as is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension. The company also develops CF102 that conducts a Phase II study for treating hepatocellular carcinoma and hepatitis C virus; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Trade Information
Trade Type
LONG
ReliabilityScore™
85.11
Entry Date
Jan 5, 2018
Entry Price
23.40
Sell Date
Jan 18, 2018
Sell Price
26.42
Net Gain
12.89%
Hold Time
8 Trading Days